Healthcare Professionals – e-Learning

Learning Objectives:

• Describe the characteristics of the influenza virus and the effect of antigenic drift
• Compare the production and effectiveness of the new cell-based vaccine with egg-based vaccines
• Implement methods to optimize immunization services

To participate in this CE program and earn 1 CEU, you must be a registered user of CanadianHealthcareNetwork.ca and its companion learning site, eCortex.ca. Registration is free and easy. Visit www.canadianhealthcarenetwork.ca to sign up.

Visit eCortex.ca to register.

This training module is intended as a refresher on how to administer the flu vaccine. The module can be completed within 30 minutes.

The iMD Patient Engagement Platform is a web-based patient education platform that is available on any device with internet. iMD Health enables healthcare providers to bring their patient sessions to life through the seamless integration of professionally-vetted diagrams, educational resources, brochures and videos covering over 1,800 medical conditions, procedures and treatment options.

To get your account, visit app.imdhealth.com/signup.

Influenza vaccination remains a critical public health tool during COVID-19 to reduce outbreaks of endemic influenza infection that have been suppressed during the COVID-19 pandemic. This program summarizes key NACI influenza vaccine recommendations and reviews the differences between the currently marketed vaccines in Canada. The overall goal of this program is to increase clinicians’ confidence in applying the NACI recommendations to the 2021-2022 influenza season.

Visit mdBriefCase to register.

N. meningitidis serogroup B strain is the most prevalent form of invasive meningococcal disease in Canada. Although this infection is relatively rare, no other bacterial agent may kill as swiftly after bloodstream invasion as the meningococcus. With the availability of vaccines to protect against the different serogroups, it is important for clinicians to educate patients on the potential risks of meningococcal infection and the benefits of immunization. This program will review the clinical consequences of meningococcal type B infection, the different vaccine options and how it can be integrated into practice.

Visit mdBriefCase to register.

Learning Objectives:

• Describe traveller cases that can be managed by primary care pharmacists.
• Educate the traveller regarding anticipated health risks and methods for prevention, based on risk assessment.
• Recommend the appropriate immunizations, and over‐the‐counter products for travelling patients who can be managed by primary care pharmacists.
• Identify high‐risk patients or destinations that require a referral to a travel medicine specialist or travel clinic.

Visit eCortex.ca to register.

This webinar will focus on immunization information-gathering and decision-making practices in vulnerable refugee and immigrant populations in the city of Edmonton, Alberta. Ms. Stephanie Kowal will present key findings and recommendations from her study on the prairies focusing particularly on the potential impact that using cultural brokers can have on the success of creating access to immunization services and promoting immunization uptake.

Visit NCCID.adobeconnect.com to hear webinar.

After viewing this webinar, participants will be better to:

• Review the current state of the COVID-19 pandemic in terms of cases, hospitalizations and deaths
• Discuss the impact of the omicron subvariant BA.2 as public health protections are removed
• Counsel a patient on the importance of booster doses to ensure optimal COVID-19 protection
• Explain the new pediatric indications and recommendations for COVID-19 vaccines
• Summarize long COVID ramifications on patients

Visit mdBriefCase to register.

Watch the recording now to listen as Drs. Allison McGeer, Earl Rubin and David Strain, with moderator Dr. Peter Lin, address the following topics:

• Omicron (as it was evolving late November)
• Boosters
  • Mix & match (aka heterologous & homogenous vaccines)
  • Immunocompromised
  • Older adults
  • Practical considerations
• Vaccine Hesitancy
• Pediatric COVID vaccination

Visit mdBriefCase to register.

This video helps clinicians discuss COVID-19 booster vaccination with their patients. The goal of the program is to help clinicians identify patients who should receive booster doses of the COVID-19 vaccines and to help build confidence in discussing booster vaccination with these patients.

Visit mdBriefCase to register.

In 2021, Health Canada approved the use of the Pfizer-BioNTech COVID-19 vaccine in children 5-11 years of age. As this population continues to get vaccinated, clinicians need to be prepared to effectively discuss the benefits and risks of vaccination against COVID-19 with parents who have children within this age group.

Visit mdBriefCase to register.

The National Advisory Committee on Immunization (NACI) recommends vaccination of adolescents aged 12 years and older with the COVID-19 vaccine. Despite broad support for vaccination from the medical community, parents and adolescents may have lingering concerns about COVID-19 vaccination. Pediatricians and other health professionals should be prepared to effectively address the questions and concerns of parents and adolescents regarding the COVID-19 vaccines.

Visit mdBriefCase to register.

Did you know? An estimated 10–30% of patients experience long COVID after recovering from their initial infection. Register for our exclusive, 1-hour webinar and learn how to effectively diagnose and treat patients who show varying symptoms causing a range of health complications post COVID.

Visit mdBriefCase to register.

mRNA vaccines have been transformational to the COVID-19 pandemic. They deliver the instructions to produce the spike protein of the SARS-CoV-2 virus to allow our immune system to mount an immune response and protect us from COVID-19. But mRNA vaccines are only one use of this technology. If the right mRNA is delivered to a specific site at the right time, it can help to address health conditions associated with a specific protein. This can lead to potential roles across multiple disease states. In this video, Dr. Melissa Moore, Chief Medical Officer of Moderna covers ten things that you should know about mRNA.

Visit mdBriefCase to register.